Taiho Oncology, Inc.
Mohammad Waseem has a diverse work experience spanning over several companies and roles. Mohammad started their career as a Medical Representative at Merck India Limited, where they analyzed the market, built relationships with healthcare professionals, and promoted product launches. Mohammad then moved on to Bioquest Solutions Private Limited, where they worked as a Medical Services Coordinator, managing CRM processes, developing key opinion leaders, and promoting products for leading healthcare brands.
In 2009, Mohammad joined Wipro Bpo Services Private Limited as a Pharmacovigilance Officer, before transitioning to APCER Life Sciences in 2010. At APCER, they held various positions including Assistant Manager Pharmacovigilance and Associate Director, Medical Affairs and Communications. In these roles, they oversaw medical information and pharmacovigilance operations for global clients, managed teams, developed strategies for process improvements, and supported health agency inspections. Mohammad also played a role in technology platform development and training department leaders.
Their most recent work experience is with Taiho Oncology, Inc., where they are an Associate Director of Medical Information Operations since 2023. Details about their specific responsibilities and achievements in this role are not provided. Overall, Mohammad has gained extensive experience in medical information, pharmacovigilance, leadership, global operations, and project management throughout their career.
Mohammad Waseem attended Jamia Hamdard from 2003 to 2007, where they pursued a Bachelor's degree in Pharmaceutical Sciences (B.Pharma).
This person is not in the org chart
This person is not in any teams
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com